Adenovirus Specific T- Lymphocytes
Adenovirus
Jessie L. AlexanderCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Adenovirus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epstein-Barr Virus Specific T-Lymphocytes Jessie L. Alexander | Phase 1/2 | CCC |
Ebv Specific T-Lymphocytes Jessie L. Alexander, MD | Phase 1/2 | CC |
Cytomegalovirus -Specific Cytotoxic T Cells Jessie L. Alexander | Phase 1/2 | CC |
Same molecule, other indications
Adenovirus Specific T- Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →